AU2016215033B2 - (9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto - Google Patents
(9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Download PDFInfo
- Publication number
- AU2016215033B2 AU2016215033B2 AU2016215033A AU2016215033A AU2016215033B2 AU 2016215033 B2 AU2016215033 B2 AU 2016215033B2 AU 2016215033 A AU2016215033 A AU 2016215033A AU 2016215033 A AU2016215033 A AU 2016215033A AU 2016215033 B2 AU2016215033 B2 AU 2016215033B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- optionally substituted
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562113316P | 2015-02-06 | 2015-02-06 | |
| US62/113,316 | 2015-02-06 | ||
| PCT/US2016/016892 WO2016127133A1 (en) | 2015-02-06 | 2016-02-05 | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016215033A1 AU2016215033A1 (en) | 2017-08-10 |
| AU2016215033B2 true AU2016215033B2 (en) | 2020-06-25 |
Family
ID=55404854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016215033A Active AU2016215033B2 (en) | 2015-02-06 | 2016-02-05 | (9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9714246B2 (enExample) |
| EP (1) | EP3253752B1 (enExample) |
| JP (1) | JP6755254B2 (enExample) |
| KR (1) | KR102586138B1 (enExample) |
| CN (1) | CN107438606B (enExample) |
| AU (1) | AU2016215033B2 (enExample) |
| CA (1) | CA2974540C (enExample) |
| ES (1) | ES2960717T3 (enExample) |
| IL (1) | IL253704B (enExample) |
| MX (1) | MX375718B (enExample) |
| RU (1) | RU2736509C2 (enExample) |
| WO (1) | WO2016127133A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3155599A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| MX375718B (es) | 2015-02-06 | 2025-03-06 | Neurocrine Biosciences Inc | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. |
| LT3875459T (lt) | 2015-10-30 | 2024-02-26 | Neurocrine Biosciences, Inc. | Valbenazino dihidrochlorido druskos ir jų polimorfai |
| CA3009169A1 (en) | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| JP7090151B2 (ja) | 2017-01-27 | 2022-06-23 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JOP20190239A1 (ar) * | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| MA50175B1 (fr) | 2017-09-21 | 2025-05-30 | Neurocrine Biosciences, Inc. | Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| AU2017435893B2 (en) | 2017-10-10 | 2023-06-29 | Neurocrine Biosciences, Inc | Methods for the administration of certain VMAT2 inhibitors |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| WO2019241555A1 (en) | 2018-06-14 | 2019-12-19 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| WO2020070236A1 (en) | 2018-10-04 | 2020-04-09 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| MA56226A (fr) | 2018-12-07 | 2022-04-20 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| CN118252829A (zh) * | 2019-09-27 | 2024-06-28 | 纽罗克里生物科学有限公司 | Crf受体拮抗剂及使用方法 |
| HRP20250868T1 (hr) | 2021-03-22 | 2025-09-26 | Neurocrine Biosciences, Inc. | Vmat2 inhibitori i postupci za uporabu |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008058261A1 (en) * | 2006-11-08 | 2008-05-15 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54125699A (en) * | 1978-03-17 | 1979-09-29 | Nippon Chemiphar Co Ltd | Preparation of ( ) dihydroprotoemetine |
| RU2339636C2 (ru) * | 2003-06-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг | Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv) |
| RU2339363C2 (ru) | 2006-12-28 | 2008-11-27 | Лидия Ибрагимовна Гайсанова | Мазь "бунхо", обладающая противовоспалительным и регенерирующим действием |
| CN106061506A (zh) | 2014-02-07 | 2016-10-26 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| MX375718B (es) | 2015-02-06 | 2025-03-06 | Neurocrine Biosciences Inc | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. |
-
2016
- 2016-02-05 MX MX2017010062A patent/MX375718B/es active IP Right Grant
- 2016-02-05 CN CN201680008945.5A patent/CN107438606B/zh active Active
- 2016-02-05 KR KR1020177024606A patent/KR102586138B1/ko active Active
- 2016-02-05 EP EP16705684.5A patent/EP3253752B1/en active Active
- 2016-02-05 US US15/017,480 patent/US9714246B2/en active Active
- 2016-02-05 JP JP2017541333A patent/JP6755254B2/ja active Active
- 2016-02-05 ES ES16705684T patent/ES2960717T3/es active Active
- 2016-02-05 AU AU2016215033A patent/AU2016215033B2/en active Active
- 2016-02-05 WO PCT/US2016/016892 patent/WO2016127133A1/en not_active Ceased
- 2016-02-05 RU RU2017130514A patent/RU2736509C2/ru active
- 2016-02-05 CA CA2974540A patent/CA2974540C/en active Active
-
2017
- 2017-06-19 US US15/627,145 patent/US9988382B2/en active Active
- 2017-07-27 IL IL253704A patent/IL253704B/en active IP Right Grant
-
2018
- 2018-04-30 US US15/967,187 patent/US20180273533A1/en not_active Abandoned
-
2020
- 2020-01-22 US US16/748,999 patent/US11053242B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008058261A1 (en) * | 2006-11-08 | 2008-05-15 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3253752B1 (en) | 2023-08-16 |
| CA2974540C (en) | 2023-09-26 |
| BR112017016934A2 (pt) | 2018-04-03 |
| JP6755254B2 (ja) | 2020-09-16 |
| US9988382B2 (en) | 2018-06-05 |
| US11053242B2 (en) | 2021-07-06 |
| RU2017130514A (ru) | 2019-03-07 |
| US20200262834A1 (en) | 2020-08-20 |
| US20160289226A1 (en) | 2016-10-06 |
| KR20170113620A (ko) | 2017-10-12 |
| RU2736509C2 (ru) | 2020-11-17 |
| CA2974540A1 (en) | 2016-08-11 |
| ES2960717T3 (es) | 2024-03-06 |
| NZ733899A (en) | 2024-01-26 |
| MX375718B (es) | 2025-03-06 |
| AU2016215033A1 (en) | 2017-08-10 |
| MX2017010062A (es) | 2017-11-01 |
| RU2017130514A3 (enExample) | 2019-08-27 |
| WO2016127133A1 (en) | 2016-08-11 |
| EP3253752A1 (en) | 2017-12-13 |
| IL253704B (en) | 2021-02-28 |
| EP3253752C0 (en) | 2023-08-16 |
| KR102586138B1 (ko) | 2023-10-05 |
| US20170349586A1 (en) | 2017-12-07 |
| CN107438606A (zh) | 2017-12-05 |
| US9714246B2 (en) | 2017-07-25 |
| JP2018504437A (ja) | 2018-02-15 |
| US20180273533A1 (en) | 2018-09-27 |
| CN107438606B (zh) | 2020-09-18 |
| IL253704A0 (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016215033B2 (en) | (9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | |
| DK2152258T3 (en) | Derivatives of fluorene, anthracene, xanthene, acridine dibenzosuberone AND DERIVATIVES AND USES | |
| ES2915266T3 (es) | Derivados de N-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarínico 4 (M4) para el tratamiento de enfermedades neurológicas | |
| CA3004372C (en) | Pyrimidine derivative and use thereof | |
| TWI752963B (zh) | 用於治療或預防與β-3腎上腺素受體相關病症之β-3腎上腺素受體調節劑 | |
| EP3060562B1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| EA021765B1 (ru) | Производные хиназолиндиона, их получение и их различные терапевтические применения | |
| EP3027607B1 (en) | Substituted heteroaryl compounds and methods of use thereof | |
| JP7623294B2 (ja) | 化合物、組成物および方法 | |
| UA128408C2 (uk) | Похідні 4-піразин-2-ілметилморфоліну і їх застосування як лікарського засобу | |
| JP2016000700A (ja) | ２−アミノ置換ピリジン誘導体 | |
| WO2022226182A1 (en) | Nek7 inhibitors | |
| TW202321222A (zh) | 蕈毒鹼受體4拮抗劑及使用方法 | |
| CN101597260A (zh) | 新的毒蕈碱受体拮抗剂及其用途 | |
| RU2782469C2 (ru) | Апоптоз-индуцирующие агенты | |
| KR20240115832A (ko) | 헌팅턴병을 치료하기 위한 htt 조절제 | |
| KR20240035517A (ko) | 수소화 퀴녹살린 | |
| BR112017016934B1 (pt) | Compostos inibidores do transportador vesicular de monoamina 2 (vmat2), composição farmacêutica compreendendo os mesmos, uso dos mesmos para tratar um transtorno hipercinético, esquizofrenia e transtorno bipolar e método para preparar a dita composição farmacêutica | |
| HK1226395B (en) | Substituted pyrimidine compounds and their use as syk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |